Orforglipron Hemicalcium Hydrate is an orally administered, long-acting GLP-1 receptor agonist currently in clinical development for the management of type 2 diabetes and obesity. By targeting glucagon-like… Read more
Orforglipron Hemicalcium Hydrate is an orally administered, long-acting GLP-1 receptor agonist currently in clinical development for the management of type 2 diabetes and obesity. By targeting glucagon-like peptide-1 receptors, this compound regulates glucose homeostasis and energy balance, offering a distinct mechanism of action compared to injectable therapies. This category provides essential analytical tools, including reference standards, identified impurities, metabolites, and stable isotope-labelled compounds, which are critical for rigorous quality control and method validation. Pharmaceutical laboratories utilize these materials for accurate impurity profiling and quantitative analysis throughout the drug development lifecycle. By facilitating precise identification and quantification of related substances, these reference materials ensure the integrity and regulatory compliance of the active pharmaceutical ingredient.